Follow the Everest Medicines Ltd. share price and the full management transaction log of the company, a publicly traded company based in Hong Kong. Shares are quoted on the HK market, under the oversight of HKEX. Operating in the Health Care sector, Everest Medicines Ltd. has published 20 insider filings. Market capitalisation: €10.2bn. The latest transaction was reported on 19 August 2026 (Other). Among the most active insiders: FU WEI. The full history is free.
20
Insider Decl.
n/a
Thresholds
€126m
16 ops.
Buy Volume
n/a
n/a
Sell Volume
36Σ signal
Buys €126mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,318 of 29,062 companies
33.2
score / 100
Value
26
Quality
40
FCF yld-3.7%
Earn yld-2.5%
EV/EBITDA·
ROE-1.2%
Gross mgn69%
Net mgn-17%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Everest Medicines Ltd. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para enfermedades graves en Asia. La empresa cotiza en la Bolsa de Hong Kong.